Loading clinical trials...

UNKNOWN

Fibrinogen to Albumin Ratio and C-reactive Protein to Albumin Ratio in Juvenile Idiopathic Arthritis

Correlation of Fibrinogen to Albumin Ratio and C-reactive Protein to Albumin Ratio With Disease Activity in Juvenile Idiopathic Arthritis

NCT06024486•Assiut University

View on ClinicalTrials.gov

Summary

The fibrinogen to albumin ratio (FAR) and C-reactive protein to albumin ratio (CAR) have emerged as useful biomarkers to predict systemic inflammation. The aim here is to investigate the relation between FAR/CAR and Juvenile arthritis disease activity score (JASDAS27) in Juvenile idiopathic arthritis (JIA)

Detailed Description

The JADAS27 includes a selected count of the following joints: cervical spine, elbows, wrists, metacarpophalangeal joints (from first to third), proximal interphalangeal joints, hips, knees and ankles.

Eligibility

Age

0 - 16 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•All juvenile idiopathic arthritis fulfilling the criteria of International League of Associations for Rheumatology (ILAR) and age and sex matched healthy subjects

Exclusion Criteria

•Other systemic inflammatory or autoimmune disorders.
•History of corticosteroid medication in the last 6 months.
•Liver diseases.
•Malignancy.

Key Dates

Start Date

November 1, 2023

Primary Completion Date

May 1, 2024

Completion Date

July 1, 2024

Last Updated

October 6, 2023

Enrollment

ESTIMATED participants

Conditions

Juvenile Idiopathic Arthritis

Interventions

fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)

DIAGNOSTIC_TEST

Dynamic Gait Index as a Functional Gait Assessment Measure in Children With JIA

NCT06870045

Juvenile Idiopathic ArthritisChildhood Rheumatic Disease

View study

RECRUITING

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

NCT04902807

Autoimmune Lymphoproliferative SyndromeAutoimmune Cytopenia+18 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 6, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Fibrinogen to Albumin Ratio and C-reactive Protein to Albumin Ratio in Juvenile Idiopathic Arthritis

Inclusion Criteria

Exclusion Criteria

Dynamic Gait Index as a Functional Gait Assessment Measure in Children With JIA

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults

Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis

Interest of an Adapted Physical Activity (APA) Program Among Patients With Juvenile Idiopathic Arthritis: a Feasibility and Efficacy Preliminary Study